Porcine Vaccine Market

Global Porcine Vaccine Market Size (2024 to 2029)

The size of the global porcine vaccine market is predicted to be valued at USD 1.9 Billion in 2024 and USD 2.74 Billion by 2029 and grow at a CAGR of 6.3% from 2024 to 2029. 

The porcine vaccine market involves developing, producing, and distributing vaccines designed to protect swine (pigs) from various bacteria, viruses, and pathogens. These vaccines are crucial in preventing diseases, especially with the rising demand for pork, increasing swine diseases, and higher animal healthcare spending per capita. The primary purpose of porcine vaccines is to enhance swine health by preventing diseases, contributing to increased pork consumption globally. Like other species, pig vaccination involves injectable vaccines for growing piglets, administered after maternal antibodies decrease (around three to six weeks). Pregnant sows may also be vaccinated to produce colostral antibodies for protecting newborn piglets. These vaccines improve healthcare and protect animals from diseases, indicating animal care quality.

Global Porcine Vaccine Market Drivers:

The rising demand for swine health drives the need for effective porcine vaccines to ensure health and quality. They are the rising infection diseases like porcine reproductive and respiratory syndrome virus (PRRSV) infection, the leading cause of economic casualty in the swine industry, which is driving the global market growth and an opportunity to the market participants. Growing occurrences of swine diseases underscore the necessity for vaccines, boosting their demand in the global market. With increased per capita spending on animal healthcare, there is a growing financial commitment to swine health, including vaccination. According to EMA (European Medicines Agency), 2023 witnessed significant developments in veterinary regulatory affairs. The Committee for Medicinal Products for Veterinary Use (CVMP) held a meeting in 2023, and several vital highlights emerged, such as Safety Concerns, Efficacy, Innovative Therapy, and new regulations increasing awareness and driving the global market. Factors such as the growing prevalence of swine diseases and increased per capita spending on veterinary healthcare contribute to the expanding market for porcine vaccines. 

The rising research activities by health professionals, the rising investments by the market players for developing novel vaccines to eradicate diseases, and the growing product approvals are propelling the porcine vaccine market growth. The growing awareness regarding the vaccine across the veterinary universities is expected to assist the porcine farmers in developing disease control measures. The rising demand for inactivated vaccines in recent years is expected to provide lucrative growth opportunities for market expansion. 

The development and commercialization of second-generation subunit vaccines, such as Porcilis® APP and PleuroStar APP, present opportunities for market growth. The emergence of advanced vaccine technologies, as seen in the development of Suvaxyn® CSF Marker, offers opportunities for improved disease prevention. The growing government initiatives are collaborating with other organizations to educate the farmers regarding disease control and immunization with quality animal care. 

Global Porcine Vaccine Market Restraints:

The porcine vaccine market experiences moderate economic risks, influenced by geopolitical tensions, trade policy measures, and disruptions in global supply chains. These external factors introduce uncertainties that can impact the overall stability and growth of the market. Geopolitical events and changes in trade policies may create fluctuations in the demand and supply of porcine vaccines, affecting manufacturers and stakeholders. Another restraining factor is the side effects of porcine vaccines, where the local effects such as discomfort, local swelling, reduced appetite, sneezing, mild fever, and others are expected to hamper the market growth. 

Moreover, the market faces specific challenges in developing porcine vaccines, particularly concerning the duration required to induce protective immunity. Unlike some vaccines that provide rapid immune responses, certain pig vaccines necessitate a more extended period to elicit a protective reaction from the immune system. This extended timeline poses a significant challenge in addressing immediate disease threats within swine populations. In scenarios where a swift and efficient response is crucial for disease prevention, the delayed development of protective immunity becomes a notable hurdle. 

One of the primary challenges within the porcine vaccine market revolves around the timing of vaccinations and the crucial aspect of boosting, particularly for piglets. Coordinating the optimal timing for administering vaccinations and ensuring timely and appropriate boosting presents logistical complexities. This challenge is particularly pronounced in the case of piglets, where establishing a coordinated and efficient vaccination schedule is vital for ensuring robust immunity. Overcoming this challenge requires careful planning, adherence to best practices, and integrating innovative strategies within the porcine vaccine market.

Furthermore, the global landscape of disease endemism poses a significant challenge for the porcine vaccine market. Diseases like Classical Swine Fever (CSF) persist in various parts of the world, necessitating continuous and consistent efforts for control and eradication. The endemic nature of such diseases requires ongoing vigilance and proactive measures within the porcine vaccine market to address the regional challenges of global disease endemism. 

Impact of COVID-19 on the global porcine vaccine market:

The pandemic had impacted on every field, similarly, the veterinary market faced significant impacts from the COVID-19 pandemic. In July 2020, the Centers for Disease Control and Prevention (CDC) outlined specific animal treatment regulations during the pandemic. The World Organization for Animal Health highlighted that government agencies recommended prioritizing animal healthcare in COVID-19. Developing advanced subunit vaccines presents opportunities for market expansion and improved disease prevention. Furthermore, the industry may benefit from growing investments in constructing new facilities and the increasing demand for carbon-neutral technologies, offering avenues for market growth.

REPORT COVERAGE:

The global porcine vaccine market research report has been segmented and sub-segmented based on the target disease, technology, route of administration, end-use and region.

Global Porcine Vaccine Market - By Target Disease:

• Diarrhea
• Arthritis
• Swine Influenza
• Porcine Pneumonia
• Swine Fever
• Porcine Circovirus Associated Disease 

The Porcine Circovirus Associated Disease segment is expected to account for dominant market share in the forecast period due to the rising prevalence of the disease. According to Henna's article published in MDPI Viruses in 2021, the global prevalence and status of Porcine Circovirus have resulted in a seropositivity rate of 20-80% in pigs and a high incidence rate of 60% in affected pig farms. The major market players are investing in these vaccines to gain traction globally, which fuels the market's growth. 

Global Porcine Vaccine Market - By Technology:

• Live attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Others

The Inactivated vaccines segment dominated the global market with a market share of 32% in 2023. The ease of availability, low cost, and excellent stability compared to live attenuated vaccines drive the market growth in this segment. Inactivated vaccines minimize the risk of virulence reversion after vaccination, which helps in preventing the replication of pathogens. The inactivated vaccines provide the immunity the adjuvants can enhance, fueling the growth of the adoption rate of vaccines. 

The recombinant vaccines segment is estimated to grow fastest over the forecast period. The recombinants can carry various gene inserts, working against various virus strains. 

Global Porcine Vaccine Market - By Route of Administration:

• Intravenous
• Intramuscular
• Others

The intramuscular route of administration segment held the largest share as the piglets are vaccinated intranasally in the first week of age, which was followed by the intramuscular route for all the pigs on the farm. The intramuscular route of administration is most commonly preferred to deliver the drug accurately. 

Global Porcine Vaccine Market - By End-Use:

• Hospitals
• Homecare
• Specialty Clinics
• Others

The hospital segment had a dominant market share in the global porcine vaccine market. Veterinary hospitals provide quality animal healthcare in the presence of healthcare professionals. The hospitals are highly equipped and provide the best healthcare with government guidelines. 

Global Porcine Vaccine Market - By Region:

• North America
• Europe
• Asia Pacific 
• Latin America
• Middle East and Africa

The North American region dominated the global porcine vaccine market due to the increasing consumption of pork and the rising prevalence of various swine diseases. The growing animal healthcare expenditure in developed countries like the US and Canada is driving the porcine vaccine market in the region. Technological advancements in vaccination in healthcare are adding fuel to the market expansion. 

The European region held the second position in the global market. The presence of prominent market players in the Germany and UK is driving the market in the region. The advanced healthcare infrastructure and the presence of top biotechnology and pharmaceutical companies propel the market growth.

The Asia Pacific region is projected to have significant growth during the forecast period. The growing awareness among the people regarding swine diseases and the rising advancements in biotechnology and healthcare are boosting market expansion growth. 

KEY MARKET PLAYERS:

Boehringer Ingelheim International GmbH, Zoetis, Hester Bioscience Limited, Elanco, Novartis, ARKO Laboratories, Phibro Animal Health Corporation, Dechra Pharmaceuticals, Merck & Co., Inc., Formosa Biomedical Inc. are some of the key market players in the Porcine Vaccine Market.

RECENT MARKET DEVELOPMENTS:

• In June 12, 2023, the USDA Center for Veterinary Biologics (CVB) allowed animal health company Medgene to license the production and marketing of a USDA-approved Platform Vaccine to the pork industry. The license applies to using their Platform technology to produce vaccines addressing disease targets such as Rotavirus, Porcine Circovirus, Influenza A, and Sapovirus.
• In June 2022, Merck Animal Health received license approval from the Department of Agriculture (USDA) in the United States for its Circumvent CML vaccine. The company issued a press release that claims Circumvent CML is the first-ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d.  
• In April 2022, Scientists with the United States Department of Agriculture's Agricultural Research Service (ARS) announced that a vaccine candidate for African Swine Fever (ASF) passed a vital safety test which gave regulatory approval which is beneficial for commercial stability.